Evisceration and enucleation strongly linked to ocular injuries from IEDs

Article

Ocular injuries caused by improvised explosive devices (IEDs) are strongly associated with severe ocular damage repaired by evisceration or enucleation.

Ocular injuries caused by improvised explosive devices (IEDs) are strongly associated with severe ocular damage repaired by evisceration or enucleation, states an investigation published in Eye.

Dr F.C. Erdurman et al., Department of Ophthalmology, Gulhane Military Medical Academy and School of Medicine, Ankara, Turkey, conducted a retrospective review of 61 eyes of 39 patients who had suffered from ocular injuries caused by IEDs. The average patient age was 24 years and the average follow-up was 6 months. Of the patients studied, 49 eyes had open-globe injuries and 12 eyes had closed-globe injuries.

The results showed that eyes with open-globe injury experienced a higher rate of intraocular foreign body (IOFB) injury with 76% of eyes presenting with it. Evisceration or enucleation as a primary surgical intervention was needed in 28% of eyes and 36% of eyes presented with no light perception.

At the final follow-up 43% of eyes demonstrated no light perception. In eyes that underwent vitreoretinal surgery 50% of them developed postoperative proliferative vitreoretinopathy (PVR). Postoperative PVR was identified as the most frequent cause of poor visual outcome.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.